Pregabalin Capsule
Product Images NDC 63629-8196

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl636298196)

Label (Lbl636298196)
This is a pharmaceutical product called Pregabalin Capsules, USP with a concentration of 75mg of Pregabalin, USP per capsule. The drug should be kept out of the reach of children and stored in a room temperature of 20°C-25°C. The NDC code is 63629-8196-01 and the product is sold in bottles containing 30 capsules.*
FDA Label Image

Label (Lbl6362981962)

Label (Lbl6362981962)
This is a packaging label for a generic version of Lyrica 75mg manufactured by ScieGen Pharmaceuticals. The pack contains 30 capsules and has an expiration date of MM/YY. The drug should be stored at a temperature of 20°-25°C (68°-77°F) and kept out of reach of children. The NDC number for this medication is 6362981961.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
The text appears to be a data table with two different columns providing percentages of patients improved and improvement in pain from baseline. The table seems to contain some errors, such as non-English characters and random letters and symbols, which makes it hard to interpret accurately.*
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
This text presents a chart indicating the percentage of patient improvement related to a treatment called Pregabalin. The treatment dose mentioned is 160 mg for three days. There is another chart with values of 2w, 220, 23, 20, 280, 2, 20, and 23w, but no description or context is given.*
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
This appears to be a table of medication dosages and patient improvement data for a study. The medications listed are "Fregabalin" and "Pregataiin" in different dosages, as well as a "Placebo" group. The table shows the number of patients who improved and a percentage of improvement in pain from baseline. Without further context, it is difficult to provide more specific information about the study or its findings.*
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This appears to be a data table showing the estimated percentage of subjects without LTR (not enough context to understand what LTR stands for) over a period of days, with a comparison between two treatments labeled as "Progabain" and "Placebo".*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
The text represents a chart that shows the percent of subjects who improved from baseline to week 16, using Pregabalin and Placebo. The data is presented in the form of values ranging from 100 to 280, in increments of 10, and there is a line graph that connects these values.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a calculation formula for estimating creatinine clearance (CLCT) in adult patients. The formula involves subtracting the patient's age in years from 140 and then multiplying that result by the patient's weight in kilograms. The next step involves multiplying this value by a coefficient of 0.85 for female patients. Finally, the result is obtained by multiplying the product of these calculations by the patient's serum creatinine level in milligrams per deciliter (mg/dL). This equation is often used in clinical settings to assess kidney function in adult patients.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.